In a clinical trial approved by the FDA, whose first phase has been completed, novel PEGylated AuNPs were utilized to deliver TNF into cancer cells, ending with selective TNF storage in tumor cells (Libutti et al., 2010). This evidence concerns the gene TNF and neoplasm.